Blood component manufacturing is the process where whole blood is processed to obtain varoius blood components, including red cells, platelets, and plasma.
But it is a manual process that involves more than 30 steps, limiting the ability for possible growth and affecting the quality of the final products.
Challenges go beyond manual steps. Emerging markets suffer from lack of standardization, while in those with restrictive rules speed is critical.
In all markets it is clear that the transition towards a more data-driven system must be accelerated for more streamlined processes and automation.
The pandemic and world's baby shortfall are leaving millions of open positions unanswered, as well as underskilled staff in highly skilled positions.
Price margin shrinkage
The cost of retaining and attracting donors is on the rise, resulting in component price margins decreasing in countries with private healthcare.
Global blood demand increase
Medical treatments using blood components and derivates are growing both in developed and developing countries.
Our mission is to remove manual steps and improve blood component quality and production.
To have a positive impact the solution must be sustainable, taking all blood industry dimensions and limits into account.
Preserving blood quality requires a round-the-clock process that must incorporate removing bottlenecks and manual errors.
To improve the overall manufacturing process we must enable the digital transition of manufacturing plants, and look towards the creation of smart factories.
It's a big challenge, but we're up to the task